Circulating concentrations of split products of the third complement factor (C3c and C3d) were measured in five patients before, during and after cardiopulmonary bypass. In all patients, C3d concentrations increased significantly in samples obtained after the administration of protamine sulphate. Similarly, circulating C3c was seen only in those samples obtained immediately after protamine administration. In vitro experiments demonstrated that activation of the complement system was attributable to the heparin-protamine complex, and was dose-dependent. The activation of complement was not associated with any clinically detectable adverse effects.
Activation of the complement system may cause an increase in vascular permeability (Hugli, 1979) and may be of importance in the pathogenesis of noncardiogenic pulmonary oedema (Hammerschmidt et al., 1980) . The demonstration of complement activation during cardiopulmonary bypass (CPB) (Haslam, Townsend and Branthwaite, 1980; Chenoweth et al., 1981) has led to speculation that the activation of complement may be of significance in the pathogenesis of "post-perfusion lung" (Chenoweth et al., 1981; Hammerschmidt et al., 1981) . However, in a more recent study Boralessa and colleagues (1982) were unable to show complement activation during CPB, and suggested that the changes in the concentrations of complement components were a result of dilution, redistribution or unidentified causes. Chenoweth and associates (1981) suggested that the mesh liner of bubble oxygenators caused the activation of complement, and White (1981) suggested that activation could result from the heparin-protamine complex or protamine interaction with reactive protein. We have undertaken the following study to elucidate the role of the heparin-protamine complex in complement activation during CPB using estimation of split pro- ducts of the third complement factor (C3c and C3d) in vivo and in vitro.
PATIENTS AND METHODS

Patients and cardiopulmonary bypass
Five patients, aged between 38 and 57 yr, underwent cardiac surgery for coronary bypass grafting. All patients were premedicated with morphine and hyoscine. Anaesthesia was induced with fentanyl, and was maintained using nitrous oxide in oxygen, and morphine. Neuromuscular blockade was obtained using pancuronium bromide. The operative procedure involved median sternotomy and anastomosis of reversed segments of autogenous saphenous vein from the aorta to the coronary arteries.
Heparin sulphate 3mgkg~' (Commonwealth Serum Laboratories of Australia) was given before cardiopulmonary bypass. A Sarns roller pump and a Cobe Optiflo II bubble oxygenator unit, which included an integral 0.2 urn hydrophobic bacterial gas filter, were used for all patients. The pump oxygenator system was primed with Hartmann's solution 1000 ml, 4% dextrose with 0.18% saline 1000 ml, and a further 10000 units of heparin sulphate. Arterial and venous lines were placed in the aorta and right atrium. Initial flow rate on bypass was 2.4 litre/m 2 body surface area, and the perfusate temperature was 34 °C. During bypass, flow rates were decreased to three-quarters of the initial flow and the temperature of the infusate was decreased to between 22 and 26 °C. All patients received cardioplegia solution which contained magnesium chloride 16 mmol, potassium chloride 16 mmol, and procaine hydrochloride 1 mmol litre" 1 . Total bypass time ranged from 45 to 130 min. After normal circulation was re-established, protamine sulphate (Boots Company Limited, U.K.) 6mgkg~" 1 was given i.v. over 10-15 min.
Blood samples
Blood samples were collected from the radial artery into EDTA tubes (Smmollitre" 1 ) at the following times: before the induction of anaesthesia (sample 1); 30 min after the induction of anaesthesia (sample 2); 15 min after heparinization (sample 3); 45-70 min after heparinization (sample 4); off bypass, 15 min after injection of protamine sulphate (sample 5); 3-4h after surgery (sample 6); 6-8h after surgery (sample 7); the following morning (sample 8). Plasma was separated within 30 min of collection and stored at -70 °C until assay.
In vitro experiments
Blood was collected from healthy volunteers into EDTA Smmollitre" 1 , heparin 143u./10ml and anticoagulant-free tubes, respectively. Centrifugation (2000 rev min" 1 for 15 min) was performed after 45 min at room temperature (20 °C) and serum or plasma separated. Sodium heparin (Commonwealth Serum Laboratories of Australia) was added to a final concentration of 28.6u. ml" 1 to one tube each of serum and EDTA plasma, sodium chloride 0.15 mol litre" 1 was added to one tube each of serum, EDTA plasma and heparin-derived plasma. To 200-nlitre ah'quots from each of these five tubes was added protamine sulphate lOmgml" 1 (Boots Company Limited, U. K.) in the following amounts: 0, 10, 20, 50,100,200 and 500 ng. Sodium chloride 0.15 mol litre" 1 was added to maintain a constant volume throughout. After mixing, the samples were incubated for 1 h at 37 °C. Assays for C3 split products (C3c and C3d) were performed immediately after centrif ugation at 2000 rev min" 1 for 15 min.
Electroimmunoassay
Albumin concentrations in the patient samples were measured by rocket immunoelectrophoresis (Brandslund et al., 1981) . The concentration of albumin in each patient was expressed as a percentage of the first sample obtained from the patient. C3d measurements were performed by a doublezone rocket immunoelectrophoresis as described previously (Brandslund et al., 1981; Sinosich et al., 1982) and the concentration in the patient samples given in arbitrary units. C3d concentrations in the in vitro experiments were expressed as percentage of the values seen in the control samples, EDTA plasma and heparin, serum, serum and heparin serum, and heparin plasma (all volumetrically adjusted with sodium chloride 0.15 mol litre" 1 ) C3c was demonstrated by qualitative crossed immunoelectrophoresis only (Brandslund et al., 1981) .
The antisera, that is anti-albumin (Code A114), and anti-C3c (Code 10-062) and anti-C3d (Code A063) were purchased from DAKO Immunoglobulins, Copenhagen, Denmark.
RESULTS
The circulating concentrations of C3d in the five patients undergoing cardiopulmonary bypass are shown in figure 1 . In all patients a decrease in C3d (relative to preoperative values) was seen by the time of heparinization (sample 3) soon after commencement of cardiopulmonary bypass. C3d concentrations were all significantly greater after the administration of protamine sulphate (samples 5 and 6) on completion of cardiopulmonary bypass, returning to normal values by the following morning (sample 8) in all but one patient. The albumin concentrations were lower (65-92% of the preoperative values) after commencement of bypass (sample 3), but never exceeded 105% of the preoperative value for the period of study. Crossed immunoelectrophoresis demonstrated the presence of C3c in all patients only after the administration of protamine sulphate (samples 5 and 6) ( fig. 2) .
The results of the in vitro experiments are summarized in figure 3. In the presence of heparin in both serum and plasma, the addition of protamine sulphate resulted in profound activation of the complement system (as indicated by C3d measurements), whereas no activation was observed in heparinized EDTA plasma after the addition of protamine sulphate. In the absence of heparin (in serum and EDTA plasma) no increase in C3d concentrations was seen following addition of protamine sulphate.
Similarly, an increase in the concentration of C3c was demonstrated only in heparinized serum and heparin plasma after the addition of protamine sulphate. Maximal concentrations of C3c and C3d were obtained in those samples in which the concentration of protamine sulphate necessary for coagulation of heparin-plasma was added (fig. 4) .
DISCUSSION
The presence and significance of complement activation during cardiopulmonary bypass are controversial. Chenoweth and colleagues (1981) showed increases in the plasma concentrations of C3a but not of C5a during CPB, but suggested that C5a-induced granulocyte sequestration occurred. However, Hammerschmidt and co-workers (1981) showed no evidence of C3 conversion or C5a in patient plasma, but also suggested that C5a-induced neutropaenia occurred. Haslam, Townsend and Branthwaite (1980) demonstrated conversion of C3 during both CPB and thoracotomy and, in a more recent study, Boralessa and colleagues (1982) observed a decrease in C3 and C4 during bypass. However, they obtained no evidence of changes in the C3 split product concentration and suggested that the changes were the result of dilution, redistribution, or unidentified factors, and not to activation. Although it was suggested by Chenoweth and colleagues (1981) and Hammerschmidt and coworkers (1981) that the observed changes in complement may contribute to the development of "postperfusion lung", this complication did not develop in any of the patients in either their studies or the current study.
The study performed here demonstrated no activation of C3 until protamine was administered, a finding not demonstrated in the previous studies but suggested by White (1981) . The protamineheparin complex has been shown previously to activate complement (Rent et al., 1975) , and complement activation has been demonstrated in association with an adverse response to protamine (Best et al., 1983) . The in vitro studies confirmed the necessity of both heparin and protamine to activate complement. This activation was not seen in EDTA samples in which chelation of Ca 2+ and Mg* + had occurred. Further, the effect was dose-dependent, and this may explain the difference between this study and that of Boralessa and associates (1982) in which no activation was seen. However, only onesixth of the dose of protamine had been given. The degree of complement activation observed was unlikely to be associated with an adverse response and no such response was observed. Although this does not mean that no adverse effect occurs, it may be advisable to use lower doses of protamine to decrease the likelihood of such an effect. While it is noteworthy that in none of the studies cited previously has an adverse effect of the observed activation been documented, activation of greater magnitude has been demonstrated in an anaphylactoid reaction to protamine (Best et al., 1983) and the postulated role of protamine-induced complement activation in post-perfusion lung cannot be discounted. En cinco padcntcs, se midieron antes, durante y despues de un puente extemo cardio-pulmonar, las concentracioDes circulantes de los productos teccionales del terccr factor de complemento (C3cyC3d). En todos los pacientes, las concentraciones C3d aumentaron de manera signifkante en las muestras recogidas despues de la administracion dc sulfato de protamina. Igualmente, el C3c circulante se encontraba unicamente en las muestras obtenidas inmediatamente despues de la administracion de protamina. Las experiencias in vitro demostraron que la activacion del sistema de complemento podia atribuirse al complejo heparina-protamina y dependia de las dosis. La activacion del complemento no se hallaba asociada con cualesquier efectos desfavorables clinicamente detec tables.
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